PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries reported Q1 FY26 revenue from operations of Rs 154.28 lakhs, up about 84% from Rs 83.84 lakhs in the same quarter last year. The company swung to a net profit of Rs 134.48 lakhs, compared with a loss of Rs 29.27 lakhs in Q1 FY25 and a loss of Rs 15.83 lakhs for the full FY25. Paid-up share capital rose sharply to Rs 9,026.03 lakhs from Rs 6,526.03 lakhs, indicating a fresh equity infusion of about Rs 25 crore during the quarter. Other expenses increased to Rs 13.47 lakhs versus Rs 5.35 lakhs in the year-ago quarter. The statutory auditor issued a clean limited review report with no qualifications or emphasis of matter.
For shareholders, the key takeaway is a sharp operational turnaround: revenue is growing strongly and the company has moved from losses to profits, supported by a major capital raise that strengthens the balance sheet. The stock may react positively on the swing to profitability, though the small absolute base and historical negative net worth warrant continued monitoring.